OraSure Technologies, Inc. (NASDAQ:OSUR)’s share price reached a new 52-week low during trading on Thursday . The stock traded as low as $12.50 and last traded at $13.05, with a volume of 47086 shares trading hands. The stock had previously closed at $14.72.
Several equities analysts have recently commented on the company. TheStreet downgraded OraSure Technologies from a “b” rating to a “c+” rating in a research report on Thursday. BidaskClub raised OraSure Technologies from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 24th. ValuEngine upgraded OraSure Technologies from a “hold” rating to a “buy” rating in a research note on Tuesday. Stephens cut OraSure Technologies from an “overweight” rating to an “equal weight” rating in a research note on Monday, July 16th. Finally, Raymond James reiterated a “mkt perform” rating on shares of OraSure Technologies in a research note on Tuesday, October 23rd. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $20.50.
The company has a market cap of $900.47 million, a PE ratio of 25.51, a P/E/G ratio of 3.46 and a beta of 1.52.
OraSure Technologies (NASDAQ:OSUR) last issued its quarterly earnings results on Wednesday, November 7th. The medical instruments supplier reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.02. The business had revenue of $45.90 million during the quarter, compared to analysts’ expectations of $44.50 million. OraSure Technologies had a return on equity of 6.68% and a net margin of 9.49%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.09 earnings per share. On average, equities analysts anticipate that OraSure Technologies, Inc. will post 0.34 earnings per share for the current fiscal year.
In related news, Director Charles W. Patrick sold 8,000 shares of the business’s stock in a transaction that occurred on Monday, August 27th. The stock was sold at an average price of $16.29, for a total value of $130,320.00. Following the completion of the sale, the director now directly owns 54,298 shares in the company, valued at $884,514.42. The sale was disclosed in a filing with the SEC, which is available at this link. Insiders own 2.90% of the company’s stock.
Several hedge funds have recently modified their holdings of the stock. Trexquant Investment LP bought a new stake in shares of OraSure Technologies in the third quarter valued at approximately $229,000. BlackRock Inc. boosted its stake in shares of OraSure Technologies by 5.9% in the third quarter. BlackRock Inc. now owns 8,979,357 shares of the medical instruments supplier’s stock valued at $138,732,000 after buying an additional 498,527 shares during the period. Thomson Horstmann & Bryant Inc. bought a new stake in OraSure Technologies during the third quarter worth $439,000. Campbell & CO Investment Adviser LLC bought a new stake in OraSure Technologies during the third quarter worth $187,000. Finally, Asymmetry Capital Management L.P. bought a new stake in OraSure Technologies during the third quarter worth $2,773,000. Institutional investors and hedge funds own 92.00% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This story was reported by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this story on another domain, it was illegally copied and republished in violation of US & international copyright laws. The original version of this story can be read at https://www.thelincolnianonline.com/2018/11/10/orasure-technologies-osur-hits-new-12-month-low-at-12-50.html.
OraSure Technologies Company Profile (NASDAQ:OSUR)
OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Recommended Story: Do stock splits help investors?
Receive News & Ratings for OraSure Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OraSure Technologies and related companies with MarketBeat.com's FREE daily email newsletter.